Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. - Wikidata - wikimedia - TriplyDB

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

http://www.wikidata.org/entity/Q34655667

about

Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability Oral premalignancy: the roles of early detection and chemoprevention Concordant podoplanin expression in cancer-associated fibroblasts and tumor cells is an adverse prognostic factor in esophageal squamous cell carcinoma Expression of Podoplanin in Laryngeal Squamous Cell Carcinoma and Dysplasia.Contemporary management of cancer of the oral cavity.Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.Gene expression profiling predicts the development of oral cancer.Immunohistochemical analysis of oral dysplasia: diagnostic assessment by fascin and podoplanin expression Targeting of chemoprevention to high-risk potentially malignant oral lesions: challenges and opportunities.Plant lectin can target receptors containing sialic acid, exemplified by podoplanin, to inhibit transformed cell growth and migration.Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.Higher blood vessel density in comparison to the lymphatic vessels in oral squamous cell carcinoma.SRC points the way to biomarkers and chemotherapeutic targets.Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer.New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development.DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.HuR and podoplanin expression is associated with a high risk of malignant transformation in patients with oral preneoplastic lesions.The expression of podoplanin protein is a diagnostic marker to distinguish the early infiltration of esophageal squamous cell carcinoma Biomarkers predicting malignant progression of laryngeal epithelial precursor lesions: a systematic review.Epigenetic and genetic alterations-based molecular classification of head and neck cancer.Radioimmunotherapy for high-grade glioma.Genetic regulation and potentially therapeutic application of cancer-associated fibroblasts in oral cancer.Can immunohistochemistry serve as an alternative to subjective histopathological diagnosis of oral epithelial dysplasia?Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory.First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.Podoplanin--a novel marker in oral carcinogenesis.Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia.Ebp1 activates podoplanin expression and contributes to oral tumorigenesis.Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas.High relative density of lymphatic vessels predicts poor survival in tongue squamous cell carcinoma.Immunohistochemical examination on the distribution of cells expressed lymphatic endothelial marker podoplanin and LYVE-1 in the mouse tongue tissue.Low-risk population among patients with tumor-node-metastasis stage III/IV oral squamous cell carcinoma.Evaluation of Podoplanin in Oral Leukoplakia and Oral Squamous Cell Carcinoma.Relationship of Podoplanin and Glutathione S-transferases T1 Expression with Laryngeal Cancer.Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin.

P2860

Q27310083-B512676F-B14B-4396-A645-C4572D7818DA Q27693327-8BEE066D-A771-4526-B83A-4C8392A3F3E2 Q28247458-AFB9132C-20F5-4A28-8A3D-A5127FB2FC83 Q33831924-C6AEAD0A-D973-407A-BC16-5FA9F56BA8C5 Q33866803-AC71481D-6035-4F4D-85AC-2E9938218897 Q33976619-EECF758D-90CD-4CEA-B957-395C8E92DCC9 Q34033409-CD6CDBA9-B223-4B9C-A012-69CF82496719 Q34160649-9C6A7820-4C84-4F31-9B52-D6D137A594CB Q34418880-A9CB5D68-99CB-44FA-9971-399044EECC20 Q34782013-B7B42680-7514-4D5E-AA64-67CF9FDA1091 Q35688177-8872EEE8-C9FF-4DDB-886B-05AE574E25D6 Q35963741-256725A8-4179-4595-AB74-5F1CB0FBC4D4 Q36109632-4B7E8BE9-7B34-48A5-89AC-A6392C2F712B Q36375220-E014E9F8-51C5-4C52-9826-FFC23BB8B454 Q36375624-C80A502D-DCCD-4E8F-A143-37AC76075C95 Q36443406-9FE78422-1C84-4AD5-B75C-F972D3B91319 Q36529838-53090140-2617-4657-85D7-9CF9D2A496E3 Q36648996-C0C26921-2AE4-48DA-8F75-23DD91D41482 Q37373276-ECFF94A3-F119-4979-8E21-4B260C9FCAC3 Q37406862-27CEA4FB-7DD2-401D-89BD-CA7940458CC0 Q37745911-9CE5D7EF-F1FF-493A-8BF4-8902C430F149 Q37955804-052F6A18-7BC2-43DE-9375-716BC9F5C57E Q37999072-FF62264C-7B3E-4234-B0B8-0AD03BD02FA3 Q38110937-2C0605E5-BA25-45C2-9B60-A41CF2560D31 Q38115617-39969471-AFE4-482D-ACBB-6AA4C2564D64 Q38157868-595AAB16-6C6A-4009-A0C9-90E585283B8E Q38183795-275BFC1F-68D0-4DDC-B948-DEE341075997 Q38221293-2D2017F6-9E8C-4008-B68C-950885E8EC3C Q38223220-7ECE6E57-960C-46C4-9A0A-3D6B544E375E Q38850128-F348DF02-A8DD-45C2-AEB9-E07BB151F7C6 Q38892678-65FED788-5B29-458A-8B8D-D78DD4BAA5AC Q38998641-5F1E1863-F2FE-4754-8A99-6A966650594C Q39105308-A3AC41C6-6303-4C7C-B11C-1E080328918B Q39686301-4E4348F6-6899-4F26-9735-7543B7D9E18B Q40689187-FE9D246C-D15B-45C5-BA43-86C43B71BE33 Q40733639-D78514DF-DABC-4207-ADE4-8948DEE1EAFA Q41619388-CAB2251F-20FB-4284-99E0-FCA990B09B3B Q41908609-D70E9C85-E5A0-4B1C-B848-CDB371655B92 Q41944928-E16F30AA-FFEF-4413-8FCC-34184A33754C Q42002432-8A8748D0-3ED7-4274-AA1D-A4EADD6B7B7E

P2860

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

http://www.wikidata.org/entity/Q34655667

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@ast

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@en

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@nl

type

label

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@ast

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@en

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@nl

prefLabel

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@ast

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@en

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@nl

P1433

Q34655667-68751CE7-2E31-4B08-BFFA-3FF8F1503A18

P1476

Q34655667-D2001564-7DF0-472A-8D81-0ACA4A6F70FB

P2093

Q34655667-67CB7F54-3565-4E0A-B083-29392948AF7A

Q34655667-6864A735-DA5E-4572-9C6D-187878018EC5

Q34655667-87C0D19A-FED1-4D8E-8308-311393D8C4AA

Q34655667-8BF1D125-FCE3-44EE-BC7B-E3DFC1E8D34C

Q34655667-8CDF103B-FB4F-4817-BD9F-791EC052AC54

Q34655667-915C6046-FC31-44EE-8675-FC955EC6DBAD

Q34655667-9711B785-2632-415E-876F-B7DB5A620AC1

Q34655667-ABE04DE7-0D91-402D-9B57-C8CE6779970D

Q34655667-C44F0300-9513-407C-B494-84019D00B8AD

Q34655667-E99B50D0-D498-4D8A-99D2-A8D9FEA19C5F

P304

Q34655667-6EED84A9-021B-497E-93B5-B66EFD9E2605

P31

Q34655667-1117E062-5AFF-4CCF-8F36-03BACEF62971

P356

Q34655667-5C446061-BD82-4F1C-A3DC-7C1B8E7FB6F0

P407

Q34655667-E7AFD007-8D36-43AA-A10F-3FEC212BDD03

P433

Q34655667-AD0A8ADE-9370-4B3D-99E1-3754FCE0E1BB

P478

Q34655667-859D5C35-503B-4BE9-8A21-B49E0D962C30

P577

Q34655667-054FEE0C-4B23-49F6-9264-ECC61430DDE8

P698

Q34655667-5AC51366-B158-4892-B63B-932812FB6642

P921

Q34655667-F02530D6-B371-4FBE-808E-BFA8D5FCAFBB

P356

JCO.2007.13.4072

P1433

Journal of Clinical Oncology

P1476

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

@en

P2093

Adel K El-Naggar

http://www.w3.org/2001/XMLSchema#string

Edward Kim

http://www.w3.org/2001/XMLSchema#string

Hening Ren

http://www.w3.org/2001/XMLSchema#string

Hidetoshi Kawaguchi

http://www.w3.org/2001/XMLSchema#string

J Jack Lee

http://www.w3.org/2001/XMLSchema#string

Lei Feng

http://www.w3.org/2001/XMLSchema#string

Li Mao

http://www.w3.org/2001/XMLSchema#string

Scott M Lippman

http://www.w3.org/2001/XMLSchema#string

Vali Papadimitrakopoulou

http://www.w3.org/2001/XMLSchema#string

Waun Ki Hong

http://www.w3.org/2001/XMLSchema#string

P304

354-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.13.4072

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18202409

http://www.w3.org/2001/XMLSchema#string

P921